Shots:
Grant started by highlighting the characteristics of the AVEIR DR leadless pacemaker and this pacemaker is an effective treatment for people with slower-than-normal heart rhythms
He discussed the AVEIR™ DR i2i™ IDE study's design and outcomes, which assessed the safety and performance of the world's first dual-chamber leadless pacemaker. The study effectively met all…
Shots:
Christopher started by highlighting the working of the TactiFlex Ablation Catheter and how it can be used for the treatment of patients with Atrial Fibrillation
He also talked about the study design and the key findings from the TactiFlex AF IDE trial. He later gave a comparative view of the TactiFlex catheter vs. conventional…
Shots:
Dr. Beth discussed traumatic brain injuries (TBIs) and the new TBI blood test by Abbott. She told PharmaShots how this blood test measures specific biomarkers, offering objective results within 12 hours, and aiding in evaluating suspected mild TBIs
She also talked about how Abbott’s Alinity i lab technology facilitates swift testing, complementing Abbott's i-STAT…
Shots:
Mary talked about Abbott's partnership Climate Amplified Disease and Epidemics (CLIMADE) consortium will use data science to predict, track and control diseases that may be amplified by climate change
She then spoke about how Abbott and its partners in the Abbott Pandemic Defense Coalition will provide viral sequencing and testing data as part of…
Shots:
The first quarter of 2023 highlights major acquisitions in the pharma and biotech industry along with multiple approvals. Meanwhile, Selecta and Sobi reported P-III trial (DISSOLVE I & II) results of SEL-212 for chronic refractory gout
Starting with the latest acquisitions, Pfizer acquired Seagen for ~$43B. The first quarter of the year also showcases…
Shots:
The fourth quarter of 2022 highlights approvals, multiple clinical trial results, and numerous deals. There are major alliances in this quarter which include Johnson & Johnson acquired Abiomed for ~$16.6B, Takeda entered into an agreement to acquire NDI-034858 from Nimbus Therapeutics for ~$6B
In the fourth quarter of the year, BeiGene’s Brukinsa received EC’s…
Shots:
Erika spoke about the FDA Breakthrough Device Designation received by Abbott to investigate its deep brain stimulation (DBS) system to treat treatment-resistant depression (TRD)
Erika also talked about how NeuroSphere Virtual Clinic is compatible with the deep brain stimulation (DBS) system
The interview gives an understanding of Abbott’s vision to bring life-changing technologies in…
The third quarter of 2022 highlights the approvals, clinical data & acquisitions. There are major alliances in this quarter which include CVS Health acquired Signify Health for ~$8B, Amgen acquired Chemocentryx for ~$4B
The third quarter of the year also showcases multiple approvals of the therapies which include Incyte's Opzelura US FDA's approval for Vitiligo,…
Despite the severe impact of the Covid-19 pandemic in 2020, the medical device market continued to emerge with patients' more significant needs and emerging diseases
In 2021, the medical device markets continued to supply personal protective equipment for the pandemic and new technological developments. Medtronic remains at the top of the ledger with total revenue…
While the COVID-19 pandemic has dominated the healthcare space for the last two years, some biopharma companies were involved in multiple deals, M&A, and the development of various drug candidates in other areas to diversify their portfolios
While top Biopharma companies remain on the chart, however, in 2021, new players like Moderna, BioNTech, Viatris also…

